Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.72 |
| ▸ | LMNA | P02545 | 4/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.72 |
| ▸ | POLB | P06746 | 1/20 | 0.72 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | PARP1 | P09874 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ACACB | O00763 | 1/20 | 0.48 |
| ▸ | ACACA | Q13085 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | APAF1 | O14727 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 2/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5274946 | 0.91 | PARP1 (0.66) | MAPTLMNAALDH1A1POLBL3MBTL1 | |
| SCHEMBL6097714 | 0.86 | MAPT (0.55) | MAPTLMNAALDH1A1POLBL3MBTL1 | |
| SCHEMBL17450338 | 0.83 | KCNH2 (0.58) | MAPTLMNAALDH1A1POLBL3MBTL1 | |
| SCHEMBL6097941 | 0.82 | MAPT (0.55) | MAPTLMNAALDH1A1POLBL3MBTL1 | |
| SCHEMBL6093560 | 0.81 | MAPT (0.55) | MAPTLMNAALDH1A1POLBL3MBTL1 | |
| SCHEMBL6098911 | 0.81 | MAPT (0.55) | MAPTLMNAALDH1A1POLBL3MBTL1 | |
| SCHEMBL9513154 | 0.78 | MEN1 (0.68) | MEN1KMT2A | |
| SCHEMBL5273795 | 0.78 | SLC6A4 (0.65) | PARP1 | |
| SCHEMBL6772793 | 0.77 | ACHE (0.54) | ALDH1A1PARP1 | |
| Hydrochloric Acid SCHEMBL27515762 | 0.77 | SLC6A4 (0.64) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7084143-B2 | N-(indolecarbonyl) piperazine derivatives | MERCK PATENT GMBH (DE) | 2006-08-01 | — | — | US | claimed |
| US-6838461-B1 | N-(indolcarbonyl-)piperazine derivatives | MERCK PATENT GMBH (DE) | 2005-01-04 | — | — | US | claimed |
| US-7084143-B2 | N-(indolecarbonyl) piperazine derivatives | MERCK PATENT GMBH (DE) | 2006-08-01 | — | — | US | disclosed |
| US-20050096330-A1 | N-(indolecarbonyl) piperazine derivatives | BOETTCHER HENNING (DE) | 2005-05-05 | — | — | US | disclosed |
| US-6838461-B1 | N-(indolcarbonyl-)piperazine derivatives | MERCK PATENT GMBH (DE) | 2005-01-04 | — | — | US | disclosed |
| EP-1198453-B9 | N-(INDOLCARBONYL-)PIPERAZIN DERIVATIVES | MERCK PATENT GMBH (DE) | 2004-11-10 | — | — | EP | disclosed |
| EP-1198453-B1 | N-(INDOLCARBONYL-)PIPERAZIN DERIVATIVES | MERCK PATENT GMBH (DE) | 2003-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096330-A1 | N-(indolecarbonyl) piperazine derivatives | HTR2A, HTR2B, HTR2C | MAPT 1280/4885LMNA 670/4885ALDH1A1 2239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.